Pasithea Therapeutics (KTTA) Retained Earnings (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Retained Earnings for 4 consecutive years, with -$46.4 million as the latest value for Q3 2024.
- Quarterly Retained Earnings fell 53.29% to -$46.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$46.4 million through Sep 2024, down 53.29% year-over-year, with the annual reading at -$35.3 million for FY2023, 82.46% down from the prior year.
- Retained Earnings hit -$46.4 million in Q3 2024 for Pasithea Therapeutics, down from -$8184.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$3762.0 in Q3 2021 to a low of -$46.4 million in Q3 2024.
- Historically, Retained Earnings has averaged -$14.4 million across 4 years, with a median of -$6.4 million in 2022.
- Biggest five-year swings in Retained Earnings: tumbled 183186.43% in 2022 and later surged 99.98% in 2024.
- Year by year, Retained Earnings stood at -$10561.0 in 2021, then crashed by 183186.43% to -$19.4 million in 2022, then tumbled by 82.46% to -$35.3 million in 2023, then plummeted by 31.38% to -$46.4 million in 2024.
- Business Quant data shows Retained Earnings for KTTA at -$46.4 million in Q3 2024, -$8184.0 in Q2 2024, and -$5272.0 in Q1 2024.